Cavazzoni A.; Digiacomo G.; Alfieri R.; La Monica S.; Fumarola C.; Galetti M.; Bonelli M.; Cretella D.; Barili V.; Zecca A.; Giovannetti E.; Fiorentino M.; Tiseo M.; Petronini P.G.; Ardizzoni A., Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer, «CANCERS», 2020, 12, Article number: 666 , pp. 1 - 16 [Scientific article]Open Access
Sartore-Bianchi A.; Lonardi S.; Martino C.; Fenocchio E.; Tosi F.; Ghezzi S.; Leone F.; Bergamo F.; Zagonel V.; Ciardiello F.; Ardizzoni A.; Amatu A.; Bencardino K.; Valtorta E.; Grassi E.; Torri V.; Bonoldi E.; Sapino A.; Vanzulli A.; Regge D.; Cappello G.; Bardelli A.; Trusolino L.; Marsoni S.; Siena S., Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial, «ESMO OPEN», 2020, 5, Article number: e000911 , pp. 1 - 8 [Scientific article]Open Access
Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A., Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL), «BRITISH JOURNAL OF CANCER», 2020, 123, pp. 26 - 32 [Scientific article]Open Access
Trisolini R.; Cancellieri A.; Livi V.; Annema J.T.; Ferrari M.; Natali F.; Paioli D.; Conci N.; Altimari A.; Fiorentino M.; Ardizzoni A., Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations, «LUNG CANCER», 2020, 147, pp. 204 - 208 [Scientific article]
Ponce Aix S.; Talbot D.; Govindan R.; Dols M.C.; Postmus P.E.; Lewanski C.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Ong T.J.; Morgensztern D., Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer, «FUTURE ONCOLOGY», 2020, 16, pp. 749 - 762 [Scientific article]
Cuicchi D.; Di Fabio F.; Guido A.; Llimpe F.L.R.; Morganti A.G.; Ardizzoni A.; Coscia M.; Poggioli G., Randomized Pilot Trial of Percutaneous Posterior Tibial Nerve Stimulation Versus Medical Therapy for the Treatment of Low Anterior Resection Syndrome: One-Year Follow-up, «DISEASES OF THE COLON & RECTUM», 2020, 63, pp. 1602 - 1609 [Scientific article]
Ricci C.; Capizzi E.; Giunchi F.; Casolari L.; Gelsomino F.; Rihawi K.; Natali F.; Livi V.; Trisolini R.; Fiorentino M.; Ardizzoni A., Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, Article number: 1758835920954802 , pp. 1 - 8 [Scientific article]Open Access
Di Nunno V.; Santoni M.; Mollica V.; Conti A.; Montironi R.; Battelli N.; Ardizzoni A.; Massari F., Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients, «CLINICAL DRUG INVESTIGATION», 2020, 40, pp. 211 - 226 [Scientific article]
Gatti M.; Raschi E.; Poluzzi E.; Martignani C.; Salvagni S.; Ardizzoni A.; Diemberger I., The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia, «CURRENT HEART FAILURE REPORTS», 2020, 17, pp. 365 - 383 [Scientific article]Open Access
Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A., The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter, «CLINICAL CANCER RESEARCH», 2020, 26, pp. 518 - 519 [Scientific article]
Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F., The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?, «CANCERS», 2020, 12, Article number: 3129 , pp. 1 - 21 [Scientific article]Open Access
Rizzo A.; Mollica V.; Ricci A.D.; Maggio I.; Massucci M.; Rojas Limpe F.L.; Fabio F.D.; Ardizzoni A., Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis, «FUTURE ONCOLOGY», 2020, 16, pp. 4409 - 4418 [Scientific article]
Livi, Vanina; Ardizzoni, Andrea; Cancellieri, Alessandra; Natali, Filippo; Ferrari, Marco; Paioli, Daniela; De Biase, Dario; Capizzi, Elisa; Tallini, Giovanni; Fiorentino, Michelangelo; Trisolini, Rocco, Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer, «THE CLINICAL RESPIRATORY JOURNAL», 2019, 13, pp. 590 - 597 [Scientific article]
Rihawi K ; Giannarelli D ; Galetta D ; Delmonte A ; Giavarra M ; Turci D ; Garassino M ; Tiseo M ; Barbieri ; Panni S ; Ardizzoni A;, BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. 57 - 59 [Scientific article]
Iacovelli, Roberto; Ciccarese, Chiara; Fornarini, Giuseppe; Massari, Francesco; Bimbatti, Davide; Mosillo, Claudia; Rebuzzi, Sara Elena; Di Nunno, Vincenzo; Grassi, Massimiliano; Fantinel, Emanuela; Ardizzoni, Andrea; Tortora, Giampaolo, Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2019, 85, pp. 1283 - 1289 [Scientific article]
